TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years.~* Histological or cytological documentation of non-hematologic, malignant solid tumor, excluding primary brain or spinal tumors, or history of central nervous system metastases~* At least one measurable lesion or evaluable disease~* Life expectancy of at least 12 weeks~* ECOG Performance Status of 0, 1 or 2~* PT-INR/PTT \< 1.5 x upper limit of normal \[Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists\]. Low-dose aspirin is permitted (\</= 100 mg daily).~* Adequate bone marrow, liver and renal function~* Ability to understand and to sign an informed consent form; a signed informed consent must be obtained prior to any study specific procedures~Exclusion Criteria:~* History of cardiac disease congestive heart failure (CHF) \> NYHA Class II; active coronary artery disease, myocardial infarction within 6 months prior to study entry; new onset angina within 3 months prior to study entry or unstable angina or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or Digoxin are permitted).~* Current diagnosis of type I or II diabetes mellitus or fasting blood glucose level \>125 mg/dL at screening, or HbA1c 7%~* Active clinically serious infections \> Grade 2 (NCI-CTCAE Version 3.0)~* History of having received allogeneic organ transplant~* Uncontrolled seizure disorder. Use of cytochrome P450 enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or phenobarbital) is not allowed throughout the entire study.~* Uncontrolled hypertension defined as systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg, despite optimal medical management

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copanlisib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult females, \>=18 years of age;~* inflammatory breast cancer;~* HER2-positive tumors;~* performance status 0-2.~Exclusion Criteria:~* metastases;~* previous treatment with chemotherapy, radiation therapy or hormone therapy for a breast tumor;~* clinically significant cardiovascular disease, or history of thrombotic disorders.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed active head lice infestation~Exclusion Criteria:~* Allergy to pediculicides or hair care products~* Scalp conditions other than head lice~* Previous head lice treatment within the past 4 weeks~* Current antibiotic treatment

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 24 Months
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: EXPERIMENTAL): MALG treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Pathologically confirmed T1 (\<2 cm) or T2 (\>2 cm but \< or = 4 cm) squamous cell carcinoma (SCC) of the lip or oral cavity (anterior 2/3 of the tongue, floor of mouth, lower and upper gingiva, salivary gland, hard palate, and buccal mucosa).~2. Tumor must be easily accessible, with no evidence of infection or active bleeding, encroaching major vessels or clinical evidence of neural invasion. Not previously irradiated.~3. Tumors must be amenable to surgical resection no later than 21 days post Visit 1.~4. Clinically or radiologically measurable tumor.~5. ECOG Performance Status of \< or =2.~6. Adequate renal function as demonstrated by renal creatinine clearance.~7. Adequate organ function as assessed by safety labs.~8. Agree to use effective contraception for 30 days after the last dose of study drug.~9. Absence of any serious medical conditions that would impair the subject's ability to participate.~10. Willing and able to provide written informed consent.~11. Able to return to the study site for treatment and follow-up visits as defined in the protocol.~Exclusion Criteria:~1. Known distal metastasis of the SCC of the oral cavity.~2. Systemic chemotherapy for the treatment of SCC of the head and neck less than 2 years prior to screening.~3. Concurrent documented malignancy, with the exception of localized SCC of the skin.~4. Exposure to any investigational agent within 3 months prior to screening.~5. Known allergy or hypersensitivity to platinum-containing agents.~6. Active, uncontrolled infection requiring systemic therapy.~7. Known or suspected pregnancy, planned pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-Label, Single Arm Study of PRV111 (Type: EXPERIMENTAL): Subjects received 3 treatment applications of PRV111 (Cisplatin Transmucosal System) at each of the 4 planned visits within 3 weeks prior to their tumor surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Mental Health Physician Support Program in Nova Scotia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Physician sample:~* A valid license to practice in Nova Scotia.~* The provision of informed consent.~Patient sample:~Inclusion Criteria:~* Depression defined by PHQ-9 score of \> 10.~* \> 18 years old.~* Able to read and speak English.~* Sufficiently intact cognitive functioning (physician judgement).~* Free of urgent or emergent medical or psychiatric issues e.g. unstable cardiovascular disease, suicidal ideation.~Exclusion Criteria:~* Not currently under treatment for depression either with an antidepressant medication or psychotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mental Health PSP: Physicians (Type: EXPERIMENTAL): Physicians training in Adult Mental Health Practice Support Program
- Treatment as Usual: Physicians (Type: ACTIVE_COMPARATOR): Those administering treatment as usual for depression
- Mental Health PSP: Patients (Type: EXPERIMENTAL): Those belonging to a physician who has completed the Adult Mental Health Practice Support Program training.
- Treatment as Usual: Patients (Type: ACTIVE_COMPARATOR): Those receiving treatment as usual for depression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed GIST patients who are taking imatinib~2. Age 18years or older~3. Patients experienced muscle cramps for more than 8 times (pain of NRS \> 4) or 4 times (pain of NRS \>7) within last 4 weeks~4. Life expectancy \> 6 months~5. ECOG performance status of 0-3~Exclusion Criteria:~1. Patients with renal disease receiving hemodialysis~2. Liver Cirrhosis patients with Child-Pugh class B or C~3. Patients with history of hypersensitivity to drugs including L-carnitine or nutritional supplements~4. Patients with history of spinal cord injury, peripheral vascular disease, or \> Grade 2 peripheral sensory neuropathy~5. Patients with clinically significant electrolyte imbalances such as hypocalcemia, hypokalemia, and hypomagnesaemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- L-carnitine (Type: ACTIVE_COMPARATOR): L-carnitine 500mg three times daily (per oral)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 500mg three times daily (per oral)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (Male \& female) ≥40 years of age~* Type 2 DM~* Best corrected visual acuity ≥ 20/200 (Snellen equivalent using Early Treatment Diabetic Retinopathy Study chart)~* central retinal thickness of ≥300 µm on optical coherence tomography~* nonproliferative diabetic retinopathy (NPDR) with diabetic macular edema~Exclusion Criteria:~* proliferative diabetic retinopathy~* Vitreous hemorrhage~* previous history of vitreoretinal surgery, post-cataract operation status (≤4 months before participation in this study)~* prior treatment with anti-VEGF drugs, intraocular corticosteroids, and/or retinal laser application~* Uncontrolled hypertension.~* Uncontrolled glaucoma.~* If both eyes met the study inclusion criteria, the more severely affected eye was selected

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lucentis (Type: EXPERIMENTAL): Patients were administered 0.5-mg IVR injections monthly for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Good general health as judged by the investigator, based on medical history, physical examination including 12-lead ECG (electrocardiogram), vital signs, and blood and urinary laboratory assessments~* Age, young subjects: age 18-45 years (both incl.)~* Age, elderly subjects: age at least 65 years~* Body Mass Index (BMI) 18-30 kg/m\^2 (both incl.)~* Blood pressure, young: Diastolic 50-90 mmHg, systolic 90-140 mmHg~* Blood pressure, elderly: Diastolic 50-95 mmHg, systolic 92-160 mmHg~Exclusion Criteria:~* History of any clinically significant renal, hepatic, cardiovascular, pulmonary, gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric disease, or other major disorders that could interfere with the objectives of the trial, as judged by the investigator~* Impaired renal function~* Any clinically significant abnormal ECG (electrocardiogram)~* Active hepatitis B and/or active hepatitis C~* Positive HIV (human immunodeficiency virus) antibodies~* Febrile illness within 5 days prior to first administration of liraglutide~* History of alcoholism or drug abuse during the last 12 months~* Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco products~* Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Elderly (Type: EXPERIMENTAL): None
- Young (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a confirmed diagnosis of FFR, defined as a minimum 2-month history of faecal impaction, plus at least one of the following:~  * \< 3 bowel movements per week at the toilet;~ * A history of soiling;~* Male and female subjects ≥ 4 to ≤ 12 years of age, with a Tanner stage 1 of 2 or less;~* Weight-height proportionality for age within the 5th and 95th percentile;~* Written informed consent, signed by the subject's legal guardian and by the investigator, and;~* Subject assent documented in the form of a note-to-file in the subject's source documentation.~Exclusion Criteria:~* Requirement for any medication during the period of the trial;~* Evidence by examination or laboratory tests of abnormal growth;~* An abnormal neurologic examination;~* Cystic fibrosis;~* History of, or current anorectal malformations;~* Diagnosed chromosomal abnormalities (e.g., Down's Syndrome);~* Disease state or surgery known to significantly affect the gastrointestinal absorption of drugs, or the assessment of the trial drug's effect;~* Any history, clinical and/or biochemical evidence of clinically significant renal or liver disease or cirrhosis;~* Clinically significant anaemia;~* Use of any investigational drug within the 4-week period prior to administration of trial medication.

- Gender: None
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: None

Study Arms:
- prucalopride (Type: EXPERIMENTAL): single dose 0.03 mg/kg prucalopride open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Long duration treatment with corticosteroids (started or ongoing)~Exclusion Criteria:~* History of osteogenesis imperfecta, multiple myeloma or Paget's disease~* History of Hyperparathyroidism, hyperthyroidism~* History of Osteomalacia~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study With Vortioxetine on Emotional Functioning in Patients With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a primary diagnosis of single or recurrent MDD according to DSM-5®. The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).~* The patient has had the current MDE for \<12 months.~* The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score ≥ 22 and ≤ 28 at the Baseline Visit.~* The patient has been treated with SSRI/SNRI monotherapy (citalopram, escitalopram, paroxetine, duloxetine or venlafaxine) for at least 6 weeks at adequate dose for the current MDE and with an inadequate response and is a candidate for a switch in the investigator's opinion.~* The patient wants to switch antidepressant treatment.~* The patient has an ODQ total score ≥50 at baseline, while on SSRI/SNRI monotherapy (prior to switch).~* The patient answered Yes to the screening question on emotional effects.~Exclusion Criteria:~- The patient has a significant risk of suicide according to the investigator's clinical judgment or has made an actual suicide attempt in the previous 6 months prior to Baseline~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Vortioxetine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Indiaclen Short Course Amoxycillin Therapy for Pneumonia With Wheeze

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Children aged 2-59 months with non-severe pneumonia based on WHO criteria of respiratory rate above the age specific cut-off, audible / ausculatory wheeze, accessible to follow up, whose guardians give written informed consent.~Exclusion Criteria:~* Children with severe disease, received any documented antibiotic treatment in the past 48 hours, diagnosed asthmatic on maintenance therapy, complicating acute non-pulmonary or chronic illness, known drug allergy, hospitalization in the past 2 weeks, measles or history of measles within the last month, known immunodeficiency disorder, prior enrollment in the study, residing in areas not accessible for follow-up or whose guardian refuses to consent for the study. Radiological Pneumonia on X-Ray.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Intermediate Cervical Block.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients scheduled for carotid endarterectomy in regional anesthesia~Exclusion Criteria:~* refusal to participate in the trail~* age \< 18a~* gestation/breastfeeding~* contraindication for regional anesthesia~* inclusion in other trails

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ropivacaine 0,375% (Type: EXPERIMENTAL): In the study group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,375%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.
- ropivacaine 0,75% (Type: ACTIVE_COMPARATOR): In the control group the intermediate cervical block will be performed by ultrasound guidance using 20ml ropivacaine 0,75%. Additionally 10ml prilocaine 1% will be used to infiltrate the perivascular tissue around the carotid artery. In the area of the expected incision the skin will also be infiltrated with 10ml prilocaine 1%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 60 years~* Metabolic syndrome according IDF modified criteria~* Waist circumference: Men ≥90 cm, women ≥80 cm~And two of the following criteria:~* HDL-C: Men ≤40 mg/dL, women ≤50 mg/dL~* Fasting glucose ≥100 mg/dL~* Triglycerides ≥150 mg/dL~* Blood pressure ≥130/85 mmHg~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Known hypersensibility to Irvingia gabonensis~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid disease~* Previous treatment for the metabolic syndrome components~* Body mass index ≥ 39.9 kg/m2~* Fasting glucose ≥126 mg/dL~* Triglycerides ≥ 500 mg/dL~* Total cholesterol ≥ 240 mg/dL~* LDL-C ≥190 mg/dL~* Blood pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Irvingia gabonensis (Type: EXPERIMENTAL): Irvingia gabonensis will be administered 150 mg before breakfast and 150 before dinner during 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered 150 mg before breakfast and 150 before dinner during 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete